XOMA Royalty Corporation (NASDAQ:XOMA) Receives $61.60 Consensus PT from Brokerages

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) have earned an average recommendation of “Hold” from the six brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $61.60.

Several equities research analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $97.00 price target on shares of XOMA Royalty in a research report on Friday, March 20th. Leerink Partners restated an “outperform” rating on shares of XOMA Royalty in a report on Tuesday, February 24th. Stifel Nicolaus set a $50.00 target price on XOMA Royalty in a research report on Friday, December 12th. TD Cowen upgraded XOMA Royalty to a “hold” rating in a report on Friday, February 13th. Finally, Zacks Research lowered XOMA Royalty from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 10th.

Institutional Trading of XOMA Royalty

Several hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its holdings in shares of XOMA Royalty by 13.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 543 shares in the last quarter. Russell Investments Group Ltd. lifted its position in XOMA Royalty by 3,436.4% during the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 756 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in XOMA Royalty during the fourth quarter valued at approximately $27,000. Dimensional Fund Advisors LP boosted its stake in XOMA Royalty by 4.5% in the third quarter. Dimensional Fund Advisors LP now owns 29,190 shares of the biotechnology company’s stock valued at $1,124,000 after acquiring an additional 1,269 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,523 shares in the last quarter. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Royalty Stock Performance

XOMA stock opened at $30.20 on Friday. The company has a debt-to-equity ratio of 1.15, a current ratio of 3.37 and a quick ratio of 3.37. The business has a 50-day moving average price of $26.21 and a 200 day moving average price of $30.31. The company has a market capitalization of $359.68 million, a P/E ratio of 20.69 and a beta of 0.86. XOMA Royalty has a 1-year low of $18.35 and a 1-year high of $39.92.

XOMA Royalty (NASDAQ:XOMA) last issued its earnings results on Wednesday, March 18th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.16. The company had revenue of $13.76 million for the quarter, compared to analysts’ expectations of $11.13 million. XOMA Royalty had a net margin of 45.75% and a return on equity of 10.32%. As a group, equities research analysts forecast that XOMA Royalty will post -1.41 EPS for the current fiscal year.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.